Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Nicola, Personeni"'
Autor:
Marco Macagno, Valeria Pessei, Noemi Congiusta, Luca Lazzari, Sara Erika Bellomo, Fariha Idrees, Alessandro Cavaliere, Filippo Pietrantonio, Alessandra Raimondi, Eleonora Gusmaroli, Maria Giulia Zampino, Lorenzo Gervaso, Davide Ciardiello, Giuseppe Mondello, Armando Santoro, Nicola Personeni, Emanuela Bonoldi, Maria Costanza Aquilano, Emanuele Valtorta, Salvatore Siena, Andrea Sartore-Bianchi, Alessio Amatu, Erica Francesca Bonazzina, Katia Bruna Bencardino, Guido Serini, Silvia Marsoni, Ludovic Barault, Federica Di Nicolantonio, Federica Maione
Publikováno v:
Diagnostics, Vol 14, Iss 22, p 2467 (2024)
Background: O-6-methylguanine-DNA methyltransferase is responsible for the direct repair of O6-methylguanine lesions induced by alkylating agents, including temozolomide. O-6-methylguanine-DNA methyltransferase promoter hypermethylation is a well-est
Externí odkaz:
https://doaj.org/article/40652073bce64bcb9e506faa61ad1641
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Autor:
Rohini Sharma, Anjana Pillai, Thomas Urban Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Chieh‐Ju Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed Kaseb, Yi‐Hsiang Huang, Celina Ang, Masatoshi Kudo, Naoshi Nishida, Nicola Personeni, Lorenza Rimassa, David James Pinato
Publikováno v:
Hepatology Communications, Vol 6, Iss 7, Pp 1776-1785 (2022)
Abstract The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer therapies. Th
Externí odkaz:
https://doaj.org/article/e44c4fda0f48434e9cdc4675c1f8ec5f
Autor:
Gilberto Morgan, Evandro de Azambuja, Kevin Punie, Felipe Ades, Kathrin Heinrich, Nicola Personeni, Ramy Rahme, Roberto Ferrara, Kevin Pels, Marina Garassino, Michael von Bergwelt-Baildon, Gilberto Lopes, Fabrice Barlesi, Toni K. Choueiri, Howard Burris, Solange Peters
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 455-463 (2021)
The speed and spread of the COVID-19 pandemic has been affecting the entire world for the past several months. OncoAlert is a social media network made up of more than 140 oncology stakeholders: oncologists (medical, radiation, and surgical), oncolog
Externí odkaz:
https://doaj.org/article/ed3fe74491454e72beab7a65bbe5ad3b
Autor:
Petros Fessas, Muntaha Naeem, Matthias Pinter, Thomas U. Marron, David Szafron, Lorenz Balcar, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Musharraf Navaid, Pei-Chang Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Yehia I. Abugabal, Tiziana Pressiani, Nicola Personeni, Naoshi Nishida, Masatoshi Kudo, Ahmed Kaseb, Yi-Hsiang Huang, Celina Ang, Anjana Pillai, Lorenza Rimassa, Abdul Rafeh Naqash, Elad Sharon, Alessio Cortellini, David J. Pinato
Publikováno v:
Liver Cancer, Vol 10, Iss 6, Pp 583-592 (2021)
Background and Rationale: Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indicatio
Externí odkaz:
https://doaj.org/article/5b2616ec247c4eb78946d132559d4210
Autor:
Tomi Jun, Umut Ozbek, Sirish Dharmapuri, Camille Hardy-Abeloos, Huili Zhu, Jung-Yi Lin, Nicola Personeni, Tiziana Pressiani, Naoshi Nishida, Pei-Chang Lee, Chieh-Ju Lee, Hannah Hildebrand, Neil Nimkar, Sonal Paul, Petros Fessas, Muntaha Naeem, Dominik Bettinger, Uqba Khan, Anwaar Saeed, Yi-Hsiang Huang, Masatoshi Kudo, Lorenza Rimassa, Thomas U. Marron, David J. Pinato, Celina Ang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Antibiotic exposure has been associated with worse outcomes with immune checkpoint inhibitors (ICIs) in cancer patients, likely due to disruption of the gut microbiome. Other commonly prescribed medications, such as proton pump inhibitors
Externí odkaz:
https://doaj.org/article/2cd3809960ca4aa790944f7a51d499a1
Autor:
Thomas Talbot, Antonio D'Alessio, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Thomas U. Marron, Tomi Jun, Sirish Dharmapuri, Celina Ang, Anwaar Saeed, Hannah Hildebrand, Mahvish Muzaffar, Claudia A. M. Fulgenzi, Suneetha Amara, Abdul Rafeh Naqash, Anuhya Gampa, Anjana Pillai, Yinghong Wang, Uqba Khan, Pei‐Chang Lee, Yi‐Hsiang Huang, Bertram Bengsch, Dominik Bettinger, Yehia I. Mohamed, Ahmed Kaseb, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa, Naoshi Nishida, Masatoshi Kudo, Arndt Weinmann, Peter R. Galle, Ambreen Muhammed, Alessio Cortellini, Arndt Vogel, David J. Pinato
Publikováno v:
Liver International. 43:695-707
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de9627fb7cffc608fafa38ff052e6472
https://doi.org/10.1111/liv.15502
https://doi.org/10.1111/liv.15502
Autor:
Dominik Bettinger, Bo Yu, David Szafron, Yinghong Wang, Mahvish Muzaffar, Thomas Marron, Uqba Khan, Yi-Hsiang Huang, David J Pinato, Ahmed Kaseb, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Musharraf Navaid, ChiehJu Lee, Anushi Bulumulle, Sonal Paul, Petros Fessas, Neil Nimkar, Hannah Hildebrand, Tiziana Pressiani, Yehia I Abugabal, Nicola Personeni, Lorenza Rimassa, Celina Ang, Abdul Rafeh Naqash, Francesca Benevento
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Nivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment in a real-world setting is lacking.Patients and methods We performed an international
Externí odkaz:
https://doaj.org/article/a6f7c74dd48f4d2982a8f93cab08e973
Autor:
Dominik Bettinger, Bo Yu, David Szafron, Yinghong Wang, Abdul Rafeh Naqash, Mahvish Muzaffar, Uqba Khan, Yi-Hsiang Huang, David J Pinato, Ahmed Kaseb, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Musharraf Navaid, ChiehJu Lee, Anushi Bulumulle, Sonal Paul, Petros Fessas, Neil Nimkar, Hannah Hildebrand, Tiziana Pressiani, Yehia I Abugabal, Nicola Personeni, Jingky Lozano-Kuehne, Lorenza Rimassa, Celina Ang, Thomas U Marron
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
The impact of corticosteroid therapy (CT) on efficacy of immune checkpoint inhibitors (ICI) is undefined in hepatocellular carcinoma (HCC). We evaluated whether CT administered at baseline (bCT) or concurrently with ICI (cCT) influences overall (OS),
Externí odkaz:
https://doaj.org/article/fd5dfa2eba3b4f96a6696a68a05a1a49
Publikováno v:
Health Science Reports, Vol 3, Iss 1, Pp n/a-n/a (2020)
Externí odkaz:
https://doaj.org/article/72deb294f4db46898e7d72e0cc4e1d08
Publikováno v:
Drugs in Context, Vol 7, Pp 1-10 (2018)
Over the past ten years, sorafenib, a multikinase inhibitor, has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Whereas only recently lenvatinib was shown to be noninferior
Externí odkaz:
https://doaj.org/article/b1c7f61d063c402eb64166d571babefb